dabigatran has been researched along with Fatty Liver, Nonalcoholic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Flick, MJ; Joshi, N; Kassel, KM; Kopec, AK; Luyendyk, JP; Sullivan, BP; Towery, KL | 1 |
| Adelmeijer, J; Bos, S; Boyett, SL; Daita, K; Lisman, T; Potze, W; Sanyal, AJ; Siddiqui, MS | 1 |
2 other study(ies) available for dabigatran and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice.
Topics: Alanine Transaminase; Animals; Benzimidazoles; beta-Alanine; Bile Acids and Salts; Dabigatran; Diet, High-Fat; Fatty Liver; Fibrin; Gene Expression; Inflammation; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Thrombin; Weight Gain | 2014 |
Changes of in vitro potency of anticoagulant drugs are similar between patients with cirrhosis due to alcohol or non-alcoholic fatty liver disease.
Topics: Adult; Alcoholism; Anticoagulants; Dabigatran; Enoxaparin; Female; Hemostasis; Humans; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pyrazoles; Pyridones; Thrombosis | 2017 |